Results 91 to 100 of about 480,991 (213)

Can Marburg virus be sexually transmitted?

Health Science Reports
Background and Aim Marburg virus (MARV) is a highly virulent virus of animal origin and the cause of a lethal infection (known as Marburg virus disease [MVD]) with a case‐fatality ratio ranging from 24% to 90%.
Hassan Karami, Arash Letafati, Somayeh Sadat Hosseini Fakhr   +2 more
doaj   +1 more source

Plasma proteomic profiling and molecular clustering reveal immune‐defined prognostic subtypes in lung adenocarcinoma

International Journal of Cancer, Volume 158, Issue 4, Page 858-865, 15 February 2026.
What's new? Lung adenocarcinoma shows considerable heterogeneity in disease progression and therapeutic response. Here, the authors analyzed tumor samples through proteomic profiling and applied network‐based clustering. They identified two distinct patient groups with different demographic, clinical, and molecular characteristics.
Ujjwal Neogi, Anoop T. Ambikan, Kati Turkowski, Marc A. Schneider, Vanessa M. Beutgen, Johannes Graumann, Hauke Winter, Marek Bartkuhn, Werner Seeger, Soni S. Pullamsetti, Rajkumar Savai   +10 more
wiley   +1 more source

Marburg virus disease: In a nutshell

Journal of Biomedical Sciences, 2023
No abstract available.
openaire   +1 more source

In silico exploration of deep-sea fungal metabolites as inhibitor of Ebola and Marburg VP35 and VP40.

PLoS ONE
VP30 and VP40 proteins of Ebola and Marburg viruses have been recognized as potential targets for antiviral drug development due to their essential roles in the viral lifecycle.
Abdullah R Alanzi, Mohammed F Alajmi, Mohammed S Al-Dosari, Mohammad K Parvez, Moneerah J Alqahtani   +4 more
doaj   +1 more source

Breast Health Training Program for Traditional Healers: A Pathway to Early Breast Cancer Detection in Tanzania

Cancer Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background In sub‐Saharan Africa, traditional healers often serve as primary healthcare providers and are the first point of contact for patients. Given this, they are uniquely positioned to aid in early breast cancer detection. To evaluate this, we implemented a breast cancer training program to equip traditional healers in Tanzania with ...
Autumn Beavers, Elizabeth F. Msoka, Irene Masue, Theresia Mwakyembe Mwansasu, Ayesiga Herman, Blandina T. Mmbaga, Lily Gutnik   +6 more
wiley   +1 more source

Marburg Virus Disease in Sub-Saharan Africa: A Review of Currently Available Comprehensive Genomic Data up to 2024

Zoonotic Diseases
Marburg virus (MARV) is one of the deadliest human zoonotic pathogens, historically traced back to Uganda, in East African-cave-dwelling Egyptian fruit bats (Rousettus aegyptiacus), the probable cradle of MARV.
E. Kinimi
semanticscholar   +1 more source

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.

PLoS Pathogens
Viral haemorrhagic fevers (VHF) pose a significant threat to human health. In recent years, VHF outbreaks caused by Ebola, Marburg and Lassa viruses have caused substantial morbidity and mortality in West and Central Africa.
Amy Flaxman, Sarah Sebastian, Sofia Appelberg, Kuan M Cha, Marta Ulaszewska, Jyothi Purushotham, Ciaran Gilbride, Hannah Sharpe, Alexandra J Spencer, Sagida Bibi, Daniel Wright, Isabel Schmidt, Stuart Dowall, Linda Easterbrook, Stephen Findlay-Wilson, Sarah Gilbert, Ali Mirazimi, Teresa Lambe   +17 more
doaj   +1 more source

A Phase 1 Randomized Study: Garadacimab Pharmacokinetics, Safety, and Tolerability After Administration via Autoinjector/Pre‐Filled Pen Versus Pre‐Filled Syringe in Healthy Participants

The Journal of Clinical Pharmacology, Volume 66, Issue 1, January 2026.
Abstract Garadacimab is a novel, fully human, anti‐activated factor XII monoclonal antibody approved for long‐term prophylaxis of patients with hereditary angioedema. This open‐label, parallel‐group, Phase 1, single‐center, bridging study in healthy adults (18–55 years of age) characterized the pharmacokinetics and safety of a single 200 mg ...
Fiona Glassman, John‐Philip Lawo, Mihai Alexandru Bica, Anthony Roberts, David Kormann, Ligia Chialda, Soeren Miethke, Iwona Dziadowiec, Stephen Caltabiano, Thomas Puchalski   +9 more
wiley   +1 more source

Strategic Preparedness of Broad‐Spectrum Antivirals for Rapid Response Towards Next Pandemics

Small Science, Volume 6, Issue 1, January 2026.
Nanoengineered broad‐spectrum antivirals (BSAs) represent a transformative approach to pandemic preparedness. Unlike virus‐specific drugs requiring separate development, BSAs act across multiple viral families through nanoengineering strategies that enhance solubility, bioavailability, and host‐targeted activity.
Sanoj Rejinold N, Geun‐woo Jin, Jin‐Ho Choy   +2 more
wiley   +1 more source

Immune Training of the Interleukin 6 Gene in Airway Epithelial Cells is Central to Asthma Exacerbations

Allergy, Volume 81, Issue 1, Page 157-169, January 2026.
This study aims to investigate how immune activation influences the epigenetic regulation and expression of the Interleukin‐6 (IL‐6) gene during asthma exacerbations. By examining molecular mechanisms of immune training, we seek to elucidate how IL‐6‐driven inflammatory pathways contribute to airway dysfunction and worsening asthma symptoms.
Lars P. Lunding, Markus Weckmann, Ulrich M. Zissler, Constanze Jakwerth, Rebecca Bodenstein‐Sgró, Sina Webering, Christina Vock, Johanna C. Ehlers, Romina A. M. Fernandez Ceballos, Sai Sneha Priya Nemani, Karosham Diren Reddy, Brian George G. Oliver, Cornelis J. Vermeulen, Maarten van de Berge, Carole Ober, Axel Künstner, Hauke Busch, Inke König, Christoph Garbers, Carsten B. Schmidt‐Weber, Marcel F. Nold, Ali Önder Yildirim, Claudia A. Nold‐Petry, Zane Orinska, Thomas Bahmer, Jan Heyckendorf, Gesine Hansen, Erika von Mutius, Klaus F. Rabe, Anna‐Maria Dittrich, Bianca Schaub, Folke Brinkmann, Matthias V. Kopp, Michael Wegmann, The ALLIANCE Study Group as part of the German Centre for Lung Research (DZL)   +34 more
wiley   +1 more source